AUTL · XBRL financial data

Autolus Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AUTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	10	—	—	year only	9	—	—	—	—	—
Revenue from contracts with customers	—	—	—	0	0	0*	9	21	21	24*	26	46
Cost of goods and services sold	—	year only	0	0	0	11*	18	24	29	25*	25	20
Research and development	37	25*	31	37	40	31*	27	27	28	36*	21	28
Selling, general and administrative	—	year only	18	22	27	34*	30	30	36	36*	40	41
General and administrative	11	16*	18	22	27	—	—	—	—	—	—	—
Operating income (loss)	(48)	(41)*	(39)	(59)	(68)	(76)*	(65)	(61)	(72)	(72)*	(60)	(44)
Interest income	4	3*	7	10	8	7*	6	5	4	3*	2	2
Interest expense	5	30*	19	10	11	(31)*	10	(7)	11	23*	11	(3)
Other income (expense)	(2)	3*	(2)	1	0	0*	0	0	0	0*	0	0
Income tax expense (benefit)	(5)	12*	(0)	0	0	1*	2	0	1	(1)*	1	0
Net income (loss)	(46)	(77)*	(53)	(58)	(82)	(28)*	(70)	(48)	(79)	(90)*	(72)	(39)
Earnings per share, basic USD per share	(0.26)	(0.44)*	(0.24)	(0.22)	(0.31)	(0.10)*	(0.26)	(0.18)	(0.30)	(0.34)*	(0.27)	(0.15)
Earnings per share, diluted USD per share	(0.26)	(0.44)*	(0.24)	(0.22)	(0.31)	(0.10)*	(0.26)	(0.18)	(0.30)	(0.34)*	(0.27)	(0.15)
Weighted average shares, basic millions of shares	174	174*	222	266	266	266*	266	266	266	266*	266	266
Weighted average shares, diluted millions of shares	174	174*	222	266	266	266*	266	266	266	266*	266	266

Fiscal quarters (AUTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	256	240	759	706	657	227	96	124	86	104	131	171
Marketable securities	—	0	—	—	—	361	421	330	281	197	99	30
Accounts receivable	0	0	0	0	0	0	—	—	—	24	28	44
Inventory	—	0	—	—	—	4	15	24	28	33	33	33
Prepaid and other current assets	52	35	45	52	60	67	69	68	85	76	77	55
Total current assets	308	275	804	759	718	661	616	574	515	436	369	336
Property and equipment, net	35	35	33	33	44	50	58	66	67	64	62	61
Right-of-use asset	59	61	59	58	61	55	56	59	57	65	73	74
Total assets	406	375	901	854	827	783	746	721	662	589	527	493
Accounts payable	1	0	1	1	1	2	4	5	11	3	2	1
Accrued liabilities	31	40	38	36	47	52	50	51	52	56	47	49
Total current liabilities	38	45	44	41	52	61	67	68	83	73	64	69
Lease liability, non-current	47	48	47	46	49	50	55	61	61	67	77	78
Total liabilities	226	264	319	326	351	355	375	375	396	411	418	418
Accumulated deficit	(801)	(879)	(931)	(990)	(1,072)	(1,099)	(1,169)	(1,217)	(1,296)	(1,387)	(1,458)	(1,497)
Total stockholders' equity	181	111	582	528	477	427	371	346	265	178	109	75
Total liabilities and equity	406	375	901	854	827	783	746	721	662	589	527	493
Common shares outstanding (cover page) millions of shares	174	266	266	266	266	266	266	266	266	266	266	266

Fiscal quarters (AUTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(46)	(77)*	(53)	(58)	(82)	(28)*	(70)	(48)	(79)	(90)*	(72)	(39)
Depreciation and amortization	1*	2*	2	2*	2*	2*	2	2*	2*	2*	2	2*
Net cash from operating activities	(40)*	(25)*	(41)	(51)*	(77)*	(38)*	(76)	(73)*	(68)*	(67)*	(65)	(25)*
Purchases of property and equipment	1*	1*	1	1*	10*	11*	8	7*	4*	(1)*	3	1*
Net cash from investing activities	(1)*	(1)*	(1)	(1)*	(10)*	(384)*	(60)	96*	36*	87*	96	68*
Proceeds from issuing common stock	0*	0*	550	0*	0*	0*	0	0*	0*	0*	—	—
Net cash from financing activities	0*	0*	561	(2)*	0*	30*	0	(1)*	(2)*	(2)*	(2)	(2)*
Net change in cash	(51)*	(17)*	519	(53)*	(48)*	(430)*	(132)	28*	(38)*	18*	27	40*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Autolus Therapeutics	171	46	(25)*	266.2M	8.0 quarters	Q2 FY26 10-QJun 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2.8	45	1.9*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	58	121	(4.5)*	462.7M	7.3 quarters	Q3 FY26 10-QSep 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 11:14 AM ET. The filing on SEC.gov is the record.